Designs and adaptive analysis plans for pivotal clinical trials of therapeutics and companion diagnostics

Bibliography

• Rothenberg ML, Carbone DP, Johnson DH. Improving the evaluation of new cancer treatments: challenges and opportunities. Nat Rev Cancer 2003;3:303-9
   PubMed Web of Science ®Google Scholar
• Paik S, Taniyama Y, Geyer CE. Anthracyclines in the treatment of HER2-negative breast cancer. J Natl Cancer Inst 2008;100:2-3
   PubMed Web of Science ®Google Scholar
• Pusztai L, Ayers M, Stec J, Hortobagyi GN. Clinical application of cDNA microarrays in oncology. Oncologist 2003;8:252-8
   PubMed Web of Science ®Google Scholar
• Simon R, Altman DG. Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-85
   PubMed Web of Science ®Google Scholar
• Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26
   PubMed Web of Science ®Google Scholar
• Gennari A, Sormani MP, Pronzato P, et al. HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized clinical trials. J Natl Cancer Inst 2008;100(1):14-20
   PubMed Web of Science ®Google Scholar
• Hayes DF, Thor AD, Dressler LG, et al. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 2007;357:1496-506
   PubMed Web of Science ®Google Scholar
• Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-81
   PubMed Web of Science ®Google Scholar
• Toschi L, Cappuzzo F. Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors. Oncologist 2007;12:211-20
   PubMed Web of Science ®Google Scholar
• Khambata-Ford S, Garrett CR, Meropol NJ, et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-7
   PubMed Web of Science ®Google Scholar
• Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34
   Google Scholar
• Dobbin K, Simon R. Sample size planning for developing classifiers using high dimensional DNA expression data. Biostatistics 2007;8:101-17
   PubMed Web of Science ®Google Scholar
• Dobbin KK, Zhao Y, Simon RM. How large a training set is needed to develop a classifier for microarray data? Clin Cancer Res 2008;14:108-14
   PubMed Web of Science ®Google Scholar
• Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clin Cancer Res 2007;13:6080-6
   PubMed Web of Science ®Google Scholar
• Simon R. Diagnostic and prognostic prediction using gene expression profiles in high dimensional microarray data. Br J Cancer 2003;89:1599-604
   PubMed Web of Science ®Google Scholar
• Simon R, Lam A, Li MC, et al. Analysis of gene expression data using BRB-ArrayTools. Cancer Informatics 2007;2:11-7
   Google Scholar
• Biometric Research Branch (BRB). Available from: http://linus.nci.nih.gov
   Google Scholar
• Temple RJ. Special study designs: Early escape, enrichment, studies in non-responders. Commun Stat Theory Methods 1994;23:499-531
   Web of Science ®Google Scholar
• Temple RJ. Enrichment designs: efficiency in development of cancer treatments. J Clin Oncol 2005;23:4838-9
   PubMed Web of Science ®Google Scholar
• Schilsky RL. Target practice: oncology drug development in the era of genomic medicine. Clin Trials 2007;4:163-6
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92
   PubMed Web of Science ®Google Scholar
• Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials. Clin Cancer Res 2005;10:6759-63
   Web of Science ®Google Scholar
• Simon R, Maitournam A. Evaluating the efficiency of targeted designs for randomized clinical trials: supplement and Correction. Clin Cancer Res 2006;12:3229
   Web of Science ®Google Scholar
• Maitournam A, Simon R. On the efficiency of targeted clinical trials. Stat Med 2005;24:329-39
   PubMed Web of Science ®Google Scholar
• Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72
   PubMed Web of Science ®Google Scholar
• Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Ann Oncol 2004;15:1731-7
   PubMed Web of Science ®Google Scholar
• Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005;23(9):2020-7
   PubMed Web of Science ®Google Scholar
• Simon R, Wang SJ. Use of genomic signatures in therapeutics development. Pharmacogenomics J 2006;6:1667-173
   Google Scholar
• Song Y, Chi GYH. A method for testing a prespecified subgroup in clinical trials. Stat Med 2007;26:3535-49
   PubMed Web of Science ®Google Scholar
• Wang SJ, O'Neill RT, Hung HMJ. Approaches to evaluation of treatment effect in randomized clinical trials with genomic subset. Pharm Stat 2007;6:227-44
   PubMed Web of Science ®Google Scholar
• Jiang W, Freidlin B, Simon R. Biomarker adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect. J Natl Cancer Inst 2007;99:1036-43
   PubMed Web of Science ®Google Scholar
• Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8
   PubMed Web of Science ®Google Scholar
• Van-Cutsern E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared to best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64
   PubMed Web of Science ®Google Scholar